SunRISe-5 Trial In Progress: A phase 3, randomized, open-label study of TAR-200 compared with intravesical chemotherapy after Bacillus Calmette-Guérin in recurrent high-risk non–muscle-invasive bladder cancer Porten 1, S. Bhanvadia 2, S. Najmi 3, H. Sweiti 4, J....
Novel prognostic score for patients with metastatic bladder cancer on immunotherapy using real-world data Chauhan 1, S. Silva Diaz 2, P. Jara Martin 3, A. Gurung 4, M. Young 1, C. Wells 1, E. Nally 1, B. Szabados 1, F. Jackson-Spence 1, T. Powles 1 (1) Barts...
Efficacy and toxicity of half dose BCG therapy in bladder cancer Acharya 1 (1) Assam Cancer Care Foundation, Lakhimpur - India Objective: Bacillus Calmette–Guérin (BCG) has been successfully used as immunotherapy to treat non-muscle invasive bladder cancer...
External validation of the novel prognostic Meet-URO score in Metastatic Renal Cell Carcinoma on First Line Immune-combination therapy Authors Aruni Ghose1, Alessio Signori2, Nicholas Brown3, Sophia Haywood4, Jose Tapia5, Anupama Vijay6, Michael Cheung7, Ishika...
Clinical parameters for first-line immuno-combinations choice in metastatic renal cell carcinoma (mRCC) patients (pts): the Meet-URO 33 study Bimbatti 1, A. Signori 2, U. Basso 1, L. Fratino 3, E. Bronte 4, M. De Tursi 5, F. Pierantoni 6, C. Ortega 7, G. Zago 8, R. De...
Baseline characteristics as parameters of choice of first-line therapy in metastatic renal cell carcinoma (mRCC) patients (pts): the Meet-URO 33 study S.E. Rebuzzi 1, A. Signori 2, G. Fornarini 3, M. Buffoni 4, S. Bracarda 5, R. Iacovelli 6, S. Chiellino 7, E....
Clinical response of advanced renal carcinoma’s patients treated with small immunomodulatory proteolipid particle Caballero Aguirrechu 1, C. Mesa 2, R. Alvarez 2, L. Oliver 2, D. Gomez 1, R. Rodriguez 1, A. Rosales 1, G. Vega 1 (1) "Hermanos Ameijeiras" Hospital, La...
External validation of the Grade, Age, Nodes and Tumor (GRANT) score for patients with surgically treated papillary renal cell carcinoma Maffezzoli 1, A. Signori 2, S. Buti 1 (1) Medical Oncology Unit, University Hospital of Parma, Parma - Italy, (2) Department of...
Adopting the Sectra Lesion Tracking Tool for RECIST 1.1 in Renal Cell Cancer patients: First in the UK Pilot Study Ghose 1, S. Bhargava 1, S. Banerjee 1, R. Rabbani 1, K. Weerasinghe 1, N. Mascarenhas 1, C. Madla 1, E. Sanchez 1, J. Rendall 2, S. Boussios 1 (1) Medway...
The prognostic impact of the metastatic pattern in advanced Renal Cell Carcinoma (aRCC): a retrospective analysis of 306 patients (pts) treated with compassionate ipilimumab and nivolumab (IPI+NIVO) Gandini 1, A. Signori 2, S.E. Rebuzzi 3, G. Tortora 4, L. Galli 5, C....